icon-folder.gif   Conference Reports for NATAP  
 
 
 
 
Frailty / Aging Projections in Italy - Future challenges for clinical care of an ageing population infected with HIV: a "geriatric -HIV" modelling study
 
 
  from Jules: Research in HIV on Life Expectancy Has Excluded Patients & EStimates of Multicomorbidity, Projections for disability & multi-morbidities should be included in life expectancy studies
 
In this study in graphs below first they review the current characteristics of their patients - age, lipodystrphy [75%], prevalence of various comorbidities in Italy & in the ATHENA Cohort. Then they project into the future what will happen - prevalence of frailty, falls, and percent predicts 34% will be disabled in 15 years
.
 
-------------------------
 
"In 15 years time the HIV geriatric population [65-67 yo] will increase from 4%  to 37%"
 
"In 15 years time the most frail HIV population will increase from 24% [now, 2016]  to 48%"
 
"In 15 years time 34% of PLWH will be disabled" [burden of IADLs - independent activities of daily living]
 
  see graph below - appears to predict 30% will experience a fall in 15 years, up from 20% now
 
----------------------------------------
 
Reported by Jules Levin
18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, Sept 12-13, 2016, New York, NY
 
Guaraldi G1, De Francesco D2, Malagoli A1, Theou O3, Zona S1, Carli F1, Dolci G1, Mussini C1, Kirkland S4, Mussi C5, Cesari M6, Rockwood K7
 
1 Department of Medical and Surgical Sciences for Adults and Children, Clinic of Infectious Diseases, University of Modena and Reggio Emilia;
2 HIV Epidemiology and Biostatistics Group (HEBG) at UCL - London;
3 Geriatric Medicine Research, Dalhousie University;
4 Department of Community Health & Epidemiology, Dalhousie University;
5 Geriatrics Division, Uni- versity of Modena and Reggio Emilia, Modena, Italy;
6 Gerontopole, Centre Hospitalier Universitaire de Toulouse, Toulou- se, France;
7 (1) Geriatric Medicine Research, Dalhousie University; (2) Geriatric Medicine, Institute of Brain & Behavioural Sciences, University of Manchester
 

HIV1

HIV2

Reported by Jules Levin
18th  International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, Sept 12-13, 2016, New York, NY
 
  Guaraldi G1, De Francesco D2, Malagoli A1, Theou O3, Zona S1, Carli F1, Dolci G1, Mussini C1, Kirkland S4, Mussi C5, Cesari M6, Rockwood K7
 
  1 Department of Medical and Surgical Sciences for Adults and Children, Clinic of Infectious Diseases, University of Modena and Reggio Emilia;
2 HIV Epidemiology and Biostatistics Group (HEBG) at UCL - London;
3 Geriatric Medicine Research, Dalhousie University;
4 Department of Community Health & Epidemiology, Dalhousie University;
5 Geriatrics Division, Uni- versity of Modena and Reggio Emilia, Modena, Italy;
6 Gerontopole, Centre Hospitalier Universitaire de Toulouse, Toulou- se, France;
7 (1) Geriatric Medicine Research, Dalhousie University; (2) Geriatric Medicine, Institute of Brain & Behavioural Sciences, University of Manchester  

HIV3

HIV4

HIV5

HIV6

HIV7

HIV8

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00056-0/fulltext

HIV9

HIV10

HIV11

HIV12

HIV13

HIV14

HIV15

HIV16

HIV17

HIV18

HIV19

HIV20